深圳市鸿美诊断技术有限公司于2015年10月由中国和澳大利亚的多名科学家共同创建，是一家研发、生产和销售临床诊断和生命科学产品的高新技术企业。公司聚集了一支海外高端的专业人才团队，其中诺贝尔医学奖得主1名，“深圳市海外高层次人才”2名。公司目前主要围绕幽门螺杆菌的胃肠道疾病特色诊断项目，实现幽门螺杆菌的个体化诊断，并推动胃癌防治和肠癌筛查等临床项目。
公司拥有3000多平方米的办公及研发生产场地，包括1000平方米的GMP车间和500平方米的基因研究开发平台。公司的目标是在诺奖得主巴里·马歇尔教授的指导下，瞄准消化肿瘤精准诊疗这一前沿，努力建设成为世界一流的生物医学高端制造企业。
Shenzhen Hongmed-Infagen Co., Limited was founded in 2015 by scientists from China and Australia. It is a high-tech enterprise that has its own R&D, manufacture and sales in clinical diagnostics and life science products. The company has gathered a team of talented foreign professionals, including one Nobel Laureate in Physiology or Medicine, and two "Shenzhen Overseas High-level Talents". The company is currently focusing on the diagnosis of gastrointestinal diseases associated with Helicobacter pylori, facilitate personalized treatment on multi-drug resistant Helicobacter pylori, promotes intestinal cancer screening and the prevention of gastric cancer.
The company comprises about 3,000 square meters in Shenzhen, which includes offices, 500 square meters of R&D laboratory, and a 1000 square meters GMP manufacturing space. Under the guidance of Nobel Prize winner Professor Barry Marshall, the company's aim is to stand in the very forefront of precision diagnosis and treatment of digestive tumors and strive to become a world-class biomedical high-end manufacturing company.